Patel Lab
The Patel Lab specializes in research on clinical outcomes of patients after transplantation and cardiac amyloidosis. Our research focuses on detailed characterization of the disorder, the role of imaging in diagnosis, understanding risks and mechanisms of disease progression and evaluating novel therapeutic agents.
Our lab's goal is to identify therapies which abrogate the risk of allograft rejection and the development of transplant vasculopathy, a chronic form of rejection, in heart transplant recipients.
Personal Statement
A national leader in the area of cardiac amyloidosis, Dr. Patel serves as a principal investigator in numerous clinical drug trials and as the lead investigator of the national Cardiac Amyloidosis Registry study. Dr. Patel is also an expert in the treatment of highly sensitized heart transplant recipients, with research focused on novel desensitization protocols during the pre-transplant, perioperative and post-transplant periods, as well as the long-term management of deleterious antibodies.
Jignesh Patel
Breakthrough Research
- Conducted studies demonstrating that tacrolimus is comparable to cyclosporine (CyA) in terms of survival, freedom from rejection and freedom from cardiac allograft vasculopathy (CAV).
- Conducted studies showing that highly sensitized patients who receive pre- and post-transplantation treatment to reduce circulating antibodies against human leukocyte antigen experience a survival benefit and an increase in freedom from complications.
Publications
Learn more about the recent research publications from the Patel Lab.
Job Opportunities
We are actively recruiting students and postdocs to be our colleagues and expand lab knowledge and expertise to make important breakthroughs.
Collaborations
The Patel Lab collaborates with a wide range of investigators within Cedars-Sinai and institutions around the world.
- Paris Transplant Group
- Eliot Peyster, MD—Emory Artificial Intelligence in Genomics